Risedronate
From Ganfyd
rINN: Risedronate
Other Names
Risedronate Sodium, Actonel®
Pharmacological Information
Pharmacology Images
Risedronate in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
Contents |
Introduction
Risedronate sodium is a stronger bisphosphonate with a good evidence base
Clinical Use
Indications
Administration
Oral
dose
- Paget's disease of bone: 30mg daily for 2 months, may be repeated ater at least 2 months
- Postmenopausal osteoporosis: 5mg daily or 35mg weekly
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
- Nausea
- Diarrhoea
- Abdomenal pain and distension
- Flatulence
- Dyspepsia
- In long term use (> 7 years) atypical femoral stem fractures have been associated with alendronate and the potential for decreased bone healing and increasing differential fracture risk is a concern for all bisphosphonates due to their mechanism of action[1]
- Atrial fibrillation (subject to on going analysis by regulatory agencies).
Oral bisphosphonates
- Oesophageal ulceration
- Patient needs assessment if
- Dyspepsia
- Heart burn
- Pain on swallowing
- Retrosternal pain
- Patient needs assessment if
Nitrogen-containing bisphosphonates
- Osteonecrosis (of jaw) in dose related association
